GlassScriptPhysician profile
Harsh Shah
NPI 1861054884
$8,705.27
in general payments reported to CMS, 2019-2025
12 companies · $8,346 in 2025
The $8,346 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $194 · 2024: $165 · 2025: $8,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,430 · Food and Beverage: $3,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,429.98 |
| Food and Beverage | $3,275.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,684.28 | 2025 | Micra |
| Biotronik INC. | $2,123.42 | 2025 | Biomonitor, Rivacor 7 Dr-T |
| Biosense Webster, INC. | $2,011.18 | 2025 | Carto 3, Qdot Micro |
| Boston Scientific Corporation | $1,163.02 | 2025 | Accolade Sr |
| E.R. Squibb & Sons, L.L.C. | $195.94 | 2023-2024 | Camzyos |
| Pfizer INC. | $150.86 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $115.07 | 2023 | Verquvo |
| Abbott Laboratories | $95.40 | 2025 | Navitor, Triclip, Diamondback Peripheral |
| Abiomed | $68.39 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $36.23 | 2024-2025 | Wainua, Farxiga |
| Amgen INC. | $35.05 | 2023-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $26.43 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.